Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer
2023 · New England Journal of Medicine · 390 citations
https://doi.org/10.1056/nejmoa2307980
K
Kadoaki Ohashi
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
355
Papers
7.9K
Citations
30
h-index
77
i10-index
Kadoaki Ohashi is an academic researcher from Okayama University. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Lung Cancer Research Studies & Colorectal Cancer Treatments and Studies. The author has an h-index of 30, co-authored 302 publications.
ORCID: 0000-0002-5180-3933Papers by this author
worksMET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib
2018 · Scientific Reports · 45 citations
https://doi.org/10.1038/s41598-018-20326-z
A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY)
2019 · CHEST Journal · 36 citations
https://doi.org/10.1016/j.chest.2019.01.011
Trastuzumab Emtansine in HER2+ Recurrent Metastatic Non–Small-Cell Lung Cancer: Study Protocol
2016 · Clinical Lung Cancer · 21 citations
https://doi.org/10.1016/j.cllc.2016.06.014
Pilot evaluation of a HER2 testing in non-small-cell lung cancer
2019 · Journal of Clinical Pathology · 16 citations
https://doi.org/10.1136/jclinpath-2019-206204
Long-term spontaneous remission with active surveillance in IgG4-related pleuritis: A case report and literature review
2019 · Respiratory Medicine Case Reports · 15 citations
https://doi.org/10.1016/j.rmcr.2019.100938
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat